405 related articles for article (PubMed ID: 27549118)
1. Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?
Costa DC; de Oliveira GA; Cino EA; Soares IN; Rangel LP; Silva JL
Cold Spring Harb Perspect Biol; 2016 Oct; 8(10):. PubMed ID: 27549118
[TBL] [Abstract][Full Text] [Related]
2. The aggregation of mutant p53 produces prion-like properties in cancer.
Rangel LP; Costa DC; Vieira TC; Silva JL
Prion; 2014; 8(1):75-84. PubMed ID: 24509441
[TBL] [Abstract][Full Text] [Related]
3. Prion-like aggregation of mutant p53 in cancer.
Silva JL; De Moura Gallo CV; Costa DC; Rangel LP
Trends Biochem Sci; 2014 Jun; 39(6):260-7. PubMed ID: 24775734
[TBL] [Abstract][Full Text] [Related]
4. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.
Ano Bom AP; Rangel LP; Costa DC; de Oliveira GA; Sanches D; Braga CA; Gava LM; Ramos CH; Cepeda AO; Stumbo AC; De Moura Gallo CV; Cordeiro Y; Silva JL
J Biol Chem; 2012 Aug; 287(33):28152-62. PubMed ID: 22715097
[TBL] [Abstract][Full Text] [Related]
7. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates.
Soto C; Estrada L; Castilla J
Trends Biochem Sci; 2006 Mar; 31(3):150-5. PubMed ID: 16473510
[TBL] [Abstract][Full Text] [Related]
8. Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding.
Wang G; Fersht AR
Proc Natl Acad Sci U S A; 2015 Feb; 112(8):2443-8. PubMed ID: 25675527
[TBL] [Abstract][Full Text] [Related]
9. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.
Xu J; Reumers J; Couceiro JR; De Smet F; Gallardo R; Rudyak S; Cornelis A; Rozenski J; Zwolinska A; Marine JC; Lambrechts D; Suh YA; Rousseau F; Schymkowitz J
Nat Chem Biol; 2011 May; 7(5):285-95. PubMed ID: 21445056
[TBL] [Abstract][Full Text] [Related]
10. Prion-like aggregates: infectious agents in human disease.
Westermark GT; Westermark P
Trends Mol Med; 2010 Nov; 16(11):501-7. PubMed ID: 20870462
[TBL] [Abstract][Full Text] [Related]
11. The dominant-negative interplay between p53, p63 and p73: A family affair.
Billant O; Léon A; Le Guellec S; Friocourt G; Blondel M; Voisset C
Oncotarget; 2016 Oct; 7(43):69549-69564. PubMed ID: 27589690
[TBL] [Abstract][Full Text] [Related]
12. The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration.
Costanzo M; Zurzolo C
Biochem J; 2013 May; 452(1):1-17. PubMed ID: 23614720
[TBL] [Abstract][Full Text] [Related]
13. Prion and prion-like diseases in animals.
Aguilar-Calvo P; García C; Espinosa JC; Andreoletti O; Torres JM
Virus Res; 2015 Sep; 207():82-93. PubMed ID: 25444937
[TBL] [Abstract][Full Text] [Related]
14. The Prion Concept and Synthetic Prions.
Legname G; Moda F
Prog Mol Biol Transl Sci; 2017; 150():147-156. PubMed ID: 28838659
[TBL] [Abstract][Full Text] [Related]
15. Sulfated glycosaminoglycans mediate prion-like behavior of p53 aggregates.
Iwahashi N; Ikezaki M; Nishikawa T; Namba N; Ohgita T; Saito H; Ihara Y; Shimanouchi T; Ino K; Uchimura K; Nishitsuji K
Proc Natl Acad Sci U S A; 2020 Dec; 117(52):33225-33234. PubMed ID: 33318190
[TBL] [Abstract][Full Text] [Related]
16. The Unexposed Secrets of Prion Protein Oligomers.
Wang G; Wang M; Li C
J Mol Neurosci; 2015 Aug; 56(4):932-937. PubMed ID: 25823438
[TBL] [Abstract][Full Text] [Related]
17. Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit.
Guest WC; Silverman JM; Pokrishevsky E; O'Neill MA; Grad LI; Cashman NR
J Toxicol Environ Health A; 2011; 74(22-24):1433-59. PubMed ID: 22043906
[TBL] [Abstract][Full Text] [Related]
18. p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis.
Ghosh S; Salot S; Sengupta S; Navalkar A; Ghosh D; Jacob R; Das S; Kumar R; Jha NN; Sahay S; Mehra S; Mohite GM; Ghosh SK; Kombrabail M; Krishnamoorthy G; Chaudhari P; Maji SK
Cell Death Differ; 2017 Oct; 24(10):1784-1798. PubMed ID: 28644435
[TBL] [Abstract][Full Text] [Related]
19. Direct evidence of cellular transformation by prion-like p53 amyloid infection.
Navalkar A; Pandey S; Singh N; Patel K; Datta D; Mohanty B; Jadhav S; Chaudhari P; Maji SK
J Cell Sci; 2021 Jun; 134(11):. PubMed ID: 34085695
[TBL] [Abstract][Full Text] [Related]
20. Modulation of p53 and prion protein aggregation by RNA.
Cordeiro Y; Vieira T; Kovachev PS; Sanyal S; Silva JL
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):933-940. PubMed ID: 30826454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]